Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:59 PM EDT
544.95
+15.15 (+2.86%)
4:01:10 PM EDT: $545.20 +0.25 (+0.05%)
Products, Other Pre-Announcement

FDA Authorizes Lower Dose Of Regen-Cov Antibody Cocktail To Treat COVID-19

Published: 06/04/2021 11:21 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Authorizes Lower 1,200 Mg Intravenous and Subcutaneous Dose of Regen-cov™ (casirivimab and Imdevimab) Antibody Cocktail to Treat Patients With Covid-19.
Regeneron - Expects to Submit a Full Biologics License Application for Regen-cov in Non-hospitalized Outpatients With Covid-19 Later This Summer.
Regeneron - U.S. Government to Buy All Regen-cov Doses Delivered by June 30, 2021, May Accept Additional Doses Through September 30, 2021 at Its Discretion.
Regeneron - U.S. Government May Accept Additional Doses Through September 30, 2021 at Its Discretion, Up to a Maximum Amount of 1.25 Million Doses.
Regeneron Pharmaceuticals Inc - Expects to Deliver at Least 1 Million Regen-cov Doses to U.S. Government in Q2.